The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Izon Science sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Izon Science , previously Australo Ltd, is a provider of technology platforms for nanoparticle separation and analysis. The company’s proprietary technology platform TRPS is a technology that allows nanoparticles to be analyzed with an unparalleled level of resolution. Its qEV is a nanoparticle isolation platform employed to analyze various sample types across a broad spectrum of applications. The company’s products find application in extracellular vesicles, nanomedicines, Viruses and VLPs. Izon Science is headquartered in Addington, Christchurch, New Zealand.
The key metrics of Izon Science related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Izon Science is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Izon Science.
For a detailed understanding of the performance of Izon Science, buy the report here.